2. Academic Validation
  3. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729

Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729

  • Expert Opin Ther Pat. 2014 Apr;24(4):471-5. doi: 10.1517/13543776.2014.865725.
Peter Norman 1
Affiliations

Affiliation

  • 1 Norman Consulting , 18 Pink Lane, Burnham, Bucks, SL1 8JW , UK peter.norman2@btinternet.com.
PMID: 24283201 DOI: 10.1517/13543776.2014.865725
Abstract

This application claims two crystalline forms and inhaled formulations of a the selective phosphatidylinositol 3-kinase-δ inhibitor (PI3Kδ) inhibitor 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N, N-bis(2-methoxyethyl)hex-5-ynamide. These formulations are claimed to be useful in the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease.

Figures
Products